Dual inhibition of EGFR and ERBB2 tyrosine kinases plays a clinical biological role in suppressing the proliferation and survival of those cancer cells that are promoted by signaling pathways.50, 51, 52 For lapatinib, the responses in 310 cell lines are known, whereas 342 cell lines are without known responses. Here, EGFR is linked to cancer.